94391-50-1

Basic information

• Product Name: 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine
• Synonyms: 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine
• CAS NO: 94391-50-1
• Molecular Formula: C7H10N2S
• Molecular Weight: 154.2327
• Mol File: 94391-50-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 245.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.186±0.06 g/cm3(Predicted)
• PKA: 6.76±0.20(Predicted)
• CAS DataBase Reference: 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine(94391-50-1)
• EPA Substance Registry System: 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine(94391-50-1)

Safety Data

• Hazardous Substances Data: 94391-50-1(Hazardous Substances Data)

Upstream product

• 56700-70-0 3-(tert-butoxycarbonylamino)pyridine 
• 273-75-6 thiazolo[4,5-c]pyridine 
• 139460-10-9 3-(tert-Butoxycarbonylamino)-4-mercaptopyridine 

Relevant articles and documents

COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS

Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifiying biofilm formation inhibitors.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Facile methods for preparation of thiazolopyridine and tetrahydrothiazolopyridine derivatives

The improved routes to prepare tetrahydrothiazolo[5,4-c]-pyridine-2- carboxylic acid lithium salts (2 and 3) were developed. Route A is consisted of the improved preparation of thiazolopyridine intermediates, and Route B is applicable for a large scale synthesis of tetrahydrothiazolo[5,4-c]pyridine-2- carboxylic acid derivatives. The methods we developed may serve as facile means for preparing thiazolopyridine and tetrahydrothiazolopyridine derivatives.